title: Comparison of the hybrid capture 2 and cobas 4800 tests for detection of high-risk human papillomavirus in specimens collected in PreservCyt medium.
abstract: Clinical cervical cytology specimens (n = 466) collected in PreservCyt (Hologic Inc.) were used to evaluate the agreement between Hybrid Capture 2 (hc2; Qiagen) and cobas 4800 (c4800; Roche Molecular Diagnostics) for the detection of high-risk human papillomavirus (HR HPV) genotype infections. The agreement between the two assays was 93.8% (kappa = 0.87; 95% confidence interval, 0.828 to 0.918), with 186 and 251 concordant positive and negative results, respectively. All 186 concordant positives were confirmed using the Linear Array (LA; Roche Molecular Diagnostics) genotyping test. Of the 29 samples with discordant results (6.2%), 18 were hc2 positive and LA verified 17 as positive for HR HPV. Eleven discordant specimens were c4800 positive, and LA confirmed 5 as positive for HR HPV. As of October 2009, practice guidelines in Alberta, Canada, recommend reflex HPV testing for women over 30 years old with atypical squamous cells of undetermined significance (ASCUS) and for women over 50 years old with low-grade squamous intraepithelial lesions (LSIL) to help prioritize those who should undergo further evaluation. In this study, agreement between hc2 and c4800 results for samples from women over 30 years old with ASCUS cytology was 92.3% (n = 13), while no samples from women over 50 years old with LSIL cytology were identified for analysis.
authors.affiliation: Provincial Laboratory for Public Health (Microbiology), Calgary, Alberta, Canada. Anita.Wong@albertahealthservices.ca
authors.forename: Anita A
authors.initials: AA
authors.lastname: Wong
authors.forename: Jeff
authors.initials: J
authors.lastname: Fuller
authors.forename: Kanti
authors.initials: K
authors.lastname: Pabbaraju
authors.forename: Sallene
authors.initials: S
authors.lastname: Wong
authors.forename: George
authors.initials: G
authors.lastname: Zahariadis
mesh_terms: D000293:Adolescent; D000328:Adult; D000416:Alberta; D003470:Culture Media / Q000737:chemistry; D004279:DNA, Viral / Q000235:genetics / Q000302:isolation & purification; D005260:Female; D005838:Genotype; D006801:Humans; D008875:Middle Aged; D025202:Molecular Diagnostic Techniques / Q000379:methods*; D027383:Papillomaviridae / Q000145:classification / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000175:diagnosis*; D017410:Practice Guidelines as Topic; D013048:Specimen Handling / Q000379:methods*; D014773:Virology / Q000379:methods*; D055815:Young Adult
chemical_list: D003470:Culture Media; D004279:DNA, Viral
references.citation: Int J Cancer. 2006 Sep 1;119(5):1095-101
references.pmid: 16586444
references.citation: J Med Virol. 2001 Aug;64(4):550-9
references.pmid: 11468743
references.citation: CMAJ. 2001 Apr 3;164(7):1017-25
references.pmid: 11314432
references.citation: J Clin Microbiol. 2009 Oct;47(10):3344-7
references.pmid: 19675214
references.citation: Virology. 2010 May 25;401(1):70-9
references.pmid: 20206957
references.citation: J Virol Methods. 2008 Apr;149(1):163-6
references.pmid: 18328575
references.citation: Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):945-51
references.pmid: 11008913
references.citation: Virology. 2009 Feb 20;384(2):260-5
references.pmid: 19135222
references.citation: J Clin Pathol. 2005 Sep;58(9):946-50
references.pmid: 16126875
references.citation: J Infect Dis. 2006 Nov 1;194(9):1291-9
references.pmid: 17041856
references.citation: Cancer Lett. 2003 Aug 20;198(2):187-92
references.pmid: 12957357
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1248-54
references.pmid: 18483347
references.citation: J Clin Microbiol. 2007 Jul;45(7):2130-7
references.pmid: 17494721
references.citation: Int J Cancer. 2003 Sep 1;106(3):396-403
references.pmid: 12845680
references.citation: N Engl J Med. 1998 Feb 12;338(7):423-8
references.pmid: 9459645
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1394-9
references.pmid: 12433717
references.citation: Br J Cancer. 2003 May 19;88(10):1570-7
references.pmid: 12771924
references.citation: N Engl J Med. 2003 Feb 6;348(6):518-27
references.pmid: 12571259
references.citation: Arch Pathol Lab Med. 2003 Aug;127(8):959-68
references.pmid: 12873167
references.citation: Sex Transm Dis. 2008 May;35(5):521-7
references.pmid: 18434944
references.citation: Int J Cancer. 2002 Nov 20;102(3):237-43
references.pmid: 12397642
references.citation: J Clin Microbiol. 2008 Aug;46(8):2595-604
references.pmid: 18579716
references.citation: Br Med J (Clin Res Ed). 1986 Sep 13;293(6548):659-64
references.pmid: 3092971
references.citation: J Low Genit Tract Dis. 2007 Oct;11(4):201-22
references.pmid: 17917566
references.citation: J Natl Cancer Inst Monogr. 2003;(31):3-13
references.pmid: 12807939
references.citation: N Engl J Med. 1999 Nov 25;341(22):1633-8
references.pmid: 10572150
references.citation: J Clin Virol. 2002 Dec;25 Suppl 3:S89-97
references.pmid: 12467782
references.citation: JAMA. 2001 Dec 26;286(24):3106-14
references.pmid: 11754676
references.citation: Am J Clin Pathol. 2011 Mar;135(3):468-75
references.pmid: 21350104
references.citation: J Clin Pathol. 2004 Jan;57(1):68-72
references.pmid: 14693839
references.citation: Int J Cancer. 2000 Feb 15;85(4):486-91
references.pmid: 10699919
references.citation: J Clin Microbiol. 2011 Nov;49(11):3983-5
references.pmid: 21880968
references.citation: Infect Agent Cancer. 2009 Jun 01;4:8
references.pmid: 19486508